Michel Bouvier obtained his Ph.D. in Neurological Sciences from the Université de Montréal in 1985. Following postdoctoral studies in the laboratory of Robert J. Leftkowitz – 2012 Nobel Prize for Chemistry – at Duke University, he joined the Department of Biochemistry of the Université de Montréal in 1989 and became chairman of the Department between 1997 and 2005.
In 2005, he joined IRIC, where he served as Chief Executive Officer,from 2014 to 2024. During his career, he contributed to the development of the drug research sector in Quebec, notably by participating in the founding of the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), where he served as Chief Executive Officer,from 2011 to 2016.
He was also the founding director of the University Drug Research Group (2005-2013) and the Quebec Drug Research Network (2012-2015). Michel Bouvier held the Canada Research Chair in Cell Signaling and Molecular Pharmacology from 2001 to 2022. His work has been recognized with numerous awards and honors, including the Julius Axelrod Prize from the American Society for Pharmacology and Experimental Therapeutics (2017), the Wilder Penfield Prize from the Government of Quebec (2017), and the Killam Prize from the Canada Council for the Arts (2021). He is a member of the Royal Society of Canada and a Knight of the National Order of Quebec.
